Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HHS Importation Task Force Moves Into Writing Phase; Still Seeking Input From Health Canada

This article was originally published in The Pink Sheet Daily

Executive Summary

The task force is required to conclude its written report by the fall; however, HHS Secretary Thompson has asked the task force to share its findings as soon as possible. Canadian international pharmacy representative argues that Canadian law allows pharmacies to broker three-way international transactions to sell pharmaceuticals to U.S. customers.

You may also be interested in...



Drug Importation Debate Highlights Need For Lower Rx Prices - CMS Administrator

The findings of the HHS importation task force and the new Medicare drug benefit will lead to lower prices for consumers, CMS Administrator McClellan tells NACDS. Fairer international pricing, including reduced prices of generics in other countries, is also a way forward, he adds.

Able Unable To Reform On Its Own? Firm Seeks Consent Decree To Address Manufacturing Issues

“We are prepared to enter discussions toward a decree at FDA’s earliest convenience,” Able says in letter to FDA. Company is pursuing consent decree instead of responding to FDA Form 483 report citing manufacturing deficiencies. The letter follows CEO Maury’s resignation the previous day.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS059426

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel